The safety and antifungal efficacy of amphotericin B lipid complex (ABLC) were evaluated in 556 cases of invasive fungal infection treated through an open-label, single-patient, emergency-use study of patients who were refractory to or intolerant of conventional antifungal therapy. All 556 treatment episodes were evaluable for safety. During the course of ABLC therapy, serum creatinine levels significantly decreased from baseline (P õ .02). Among 162 patients with serum creatinine values §2.5 mg/dL at the start of ABLC therapy (baseline), the mean serum creatinine value decreased significantly from the first week through the sixth week (P £ .0003). Among the 291 mycologically confirmed cases evaluable for therapeutic response, there was a complete or partial response to ABLC in 167 (57%), including 42% (55) 
Invasive fungal infections are important causes of morbidity (DMPC) and dimyristoylphosphatidylglycerol (DMPG), are present in a 7:3 molar ratio. In the coupled state within the and mortality among immunocompromised patients. These infections include disseminated candidiasis, pulmonary aspergillipid complex, amphotericin B in vitro binds preferentially to fungal cell membranes while minimally affecting mammalian losis, zygomycosis, and fusariosis. Amphotericin B is considered the treatment of choice for most of these infections [1 - cellular membranes, possibly accounting for its reduced toxicity in vivo [8 -11] . 3]. The usefulness of amphotericin B is nevertheless limited by potentially serious adverse effects, particularly dose-limiting ABLC was recently approved by the U.S. Food and Drug Administration (FDA) for treatment of invasive fungal infecnephrotoxicity [2 -7] . Amphotericin B -induced renal impairment may warrant premature or temporary cessation of treattions in patients who are refractory to or intolerant of conventional amphotericin B therapy. The indications include invasive ment or a reduction in dosage, resulting in worsening of the infection or prolonged hospitalization [4] . aspergillosis, candidiasis, and other opportunistic mycoses. However, there are few study reports in the literature describing Amphotericin B lipid complex (ABLC; ABELCET, The Liposome Co., Princeton, NJ) was developed to reduce the toxicthe safety and efficacy of ABLC in the treatment of proven invasive fungal infections. ity and maximize the therapeutic utility of amphotericin B in the treatment of invasive fungal infections. ABLC consists of Herein we report on the open-label, single-patient emergency use of ABLC in treatment of patients with invasive mycoses amphotericin B complexed with two lipids in a 1:1 drug-tolipid molar ratio. These lipids, dimyristoylphosphatidylcholine whose infections failed to respond to previous systemic antifungal therapy, who experienced severe nephrotoxicity due to amphotericin B or other drugs, or who had preexisting renal impairment. To our knowledge, this is the largest series of patients was fulfilled: (1) the failure of previous systemic antifungal from within the normal range to above normal (ú1.5 mg/dL) or else a ú20% increase from the baseline value. treatment, including amphotericin B administered at a cumulative dose of at least 500 mg; (2) the development during antifungal therapy with amphotericin B or other drugs of nephro- The response of each patient enrolled in the study to antifungal therapy was assessed by a panel of six infectious disease dren); (3) severe acute toxicity; or (4) pretreatment renal insufficiency (a serum creatinine level of §2.5 mg/dL [221 specialists with expertise in invasive fungal infections (T.W., J.H., G.H., J.S., M.D., and A.R.). The panel's assessments were mmol/L] or a creatinine clearance rate of õ25 mL/min) that precluded treatment with amphotericin B.
based on the same set of rigorous criteria as those defined by the Mycoses Study Group, hence providing a more consistent Patients were excluded from enrollment in the study if a systemic antifungal or investigational drug was administered and objective set of evaluations. Patients were evaluable for efficacy if (1) they received at least four full doses of ABLC, concurrently with ABLC, if they were pregnant or lactating, or if they were hypersensitive to amphotericin B. Before ABLC (2) they received no concurrent systemic antifungal drugs, (3) diagnosis of an invasive fungal infection was supported by treatment was initiated, the investigator obtained approval from the local institutional review board. Written informed consent clinical as well as microbiological and/or histologic findings, and (4) the appropriate follow-up studies were performed to was obtained from all study participants or their parents.
permit an independent evaluation of therapeutic response. The clinical response in all evaluable patients was assessed as deDrug Administration fined below. There were no appreciable differences in efficacy response rates between the evaluable and the intent-to-treat On the basis of preclinical and phase II studies of ABLC, patients were to be treated with a dosage of 5.0 mg/(kgrd).
population; the largest difference was õ10%. Analysis of both the evaluable and intent-to-treat populations is reported for Investigators had the option of administering lower dosages of ABLC. ABLC was initially infused intravenously at a dosage completeness. of 2.5 mg/(kgrh) daily (2-hour infusions). Following the initial infusion, both the rate of infusion and duration of treatment
Classification of Fungal Infections
could be adjusted as clinically warranted. The daily dosage could also be reduced in the event of nephrotoxicity (an inAspergillosis. The following definitions were used for diagnoses of aspergillosis: (1) pulmonary aspergillosis: recovery crease in serum creatinine level of §0.5 mg/dL [44 mmol/L] above baseline).
of microbiologically or histologically confirmed Aspergillus species organisms from tissue or respiratory secretions from According to protocol guidelines, ABLC was to be administered for 4 weeks, but therapy could extend beyond this if an immunocompromised patient with fever and pulmonary infiltrates; (2) disseminated aspergillosis: infection due to Asperclinically indicated. For all patients, including those who had a complete or partial response, the completion of therapy was gillus species involving two or more noncontiguous tissue sites; (3) sinus aspergillosis: clinical evidence of sinusitis and recova clinical judgment made by each treating physician (investigator).
ery of Aspergillus species organisms from biopsy or aspiration specimen of sinus tissue; and (4) single-organ extrapulmonary aspergillosis: microbiologically or histologically confirmed inSafety Monitoring fection due to Aspergillus species in a single organ, other than sinuses and lungs. Renal function was assessed during treatment by measurement of serum creatinine, blood urea nitrogen (BUN), and Similar definitions of pulmonary, sinus, disseminated, and single-organ extrapulmonary infections were applied to mycoses serum potassium levels. Hepatic and hematologic parameters were assessed at least weekly. Within 24 hours of the concludue to other filamentous fungi, including Zygomycetes, Fusarium species, dematiaceous molds (causing phaeohyphomycosis), and sion of treatment, as well as 1 and 4 weeks after the last dose, diagnostic, mycological, and all laboratory evaluations were nonfusarial hyaline molds (causing hyalohyphomycosis). Candidiasis. Candidemia was diagnosed if one or more repeated.
Renal function, as measured by the serum creatinine level, blood cultures were positive for Candida species. Disseminated candidiasis was defined as histologically proven invasive candiwas assessed daily during therapy. A patient was considered to have stable renal function if the serum creatinine value diasis in two or more noncontiguous tissues or fungemia with histologically proven invasive candidiasis in one tissue site. remained within the normal range (£1.5 mg/dL) or the change from baseline was õ20%. Improvement in renal function was Single-organ candidiasis was tissue-proven invasive candidiasis in a single organ. defined as a decrease in serum creatinine level from a baseline value of §1.5 mg/dL to within the normal range or else a Cryptococcosis. CNS cryptococcosis was defined by the presence of Cryptococcus neoformans in CSF or brain tissue. ú20% decrease from the baseline value. Deterioration in renal function was defined as an increase in serum creatinine level Non-CNS cryptococcosis was defined by the presence of 
Results

Analysis of Safety Demographic Characteristics of Patients
Examination of the change in mean serum creatinine level during ABLC treatment for all patients and for those with a A total of 556 cases were enrolled between December 1990 and October 1995. The study population consisted of 551 paelevated serum creatinine level ( §2. comparison with baseline levels by the third week and continuapy, the mean serum creatinine values decreased significantly from the first week through the sixth week (P £ .0003) (figure ing through the sixth week (P õ .02) (figure 1).
As patients stop treatment for one reason or another, the 3). The linear regression line plotting serum creatinine values at the beginning and end of therapy with 95% confidence internumbers available for comparison of changes in levels of serum creatinine from baseline to any given time point change. Therevals for this population fell below the 45-degree line of identity, demonstrating significant improvement in renal function for the fore, at all time points, the baseline and mean weekly serum creatinine values are presented in the figures only for the cohort patient population receiving ABLC therapy who had previous amphotericin B-induced nephrotoxicity or who had preexisting at that time point, that is, comparing each patient's serum creatinine value at each week against their own baseline value.
renal impairment (figure 4). These patterns of improving renal function during therapy with ABLC were similar for all patient This allows a valid estimate of the change in mean serum creatinine over time and ensures that the observed improvement risk groups. Three hundred ninety-six (71%) of patients had either stable in renal function is not due to the withdrawal of patients with rising serum creatinine levels.
(51%) or improved (21%) serum creatinine levels by the end of therapy. One hundred thirty-two patients (24%) developed an The trend of improving renal function is confirmed by a scatter plot of serum creatinine values at baseline and at the increase in serum creatinine level from baseline to the end of therapy; for 63 patients the serum creatinine level increased from end of therapy for all patients (figure 2). This scatter plot shows a linear regression line with 95% confidence intervals that fall a normal value (£1.5 mg/dL) to a high value (ú1.5 mg/dL), and for 69 patients the level increased ú20% from a baseline value below the line of identity and indicate a significant decline in serum creatinine values and improvement in renal function for of ú1.5 mg/dL. Twenty-eight patients (5%) did not have sufficient serum creatinine values recorded by which to evaluate trends. patients receiving ABLC therapy.
Among 162 patients with elevated baseline serum creatinine Renal tubular toxicity was assessed by serial serum potassium and magnesium levels. Hypokalemia (serum potassium values ( §2.5 mg/dL [221 mmol/L]) at the start of ABLC ther- 
Analysis of Antifungal Efficacy
Overall response rates. The overall response rate, including complete and partial responses, for all 291 evaluable fungal infections was 57.4% (95% CI, 51% -63%; 25% complete responses and 32% partial responses). Table 5 describes the efficacy of ABLC in different types of invasive fungal infections. The response rate for infections caused by filamentous fungi was 48% (82 of 170; 95% CI, 41% -56%). Complete or partial responses were achieved in 42% of the cases of aspergillosis (55 of 130), 71% of zygomycosis (17 of 24), and 82% of fusariosis (9 of 11). wickerhamii. This response rate was similar to the 73% overall tity and indicate the tendency for serum creatinine values to decline and kidney function to improve in patients receiving ABLC therapy.
response rate observed among 15 cases of mycoses due to dimorphic fungi. However, the overall response rate for mycoses due to yeasts was significantly greater than for those due to filamentous fungi (70% (table 7) . Responses were achieved in 67% of cases of disseminated candidiasis (n Å 42), 75% of fungemia (n Å 20), and 76% of single organ candidiasis (n Å 29). No differences in therapeutic response were observed in cases of candidiasis as a function of different species of Candida. Among the 11 cases of cryptococcosis, of which 6 were CNS and 5 were non-CNS infections, the response rates in each group were 50% and 80%, respectively.
Efficacy and underlying condition. The overall response rate in this study varied in relation to the primary underlying condition. Table 8 summarizes response rates according to underlying conditions. Among the highest response rates were those observed among patients with hematologic malignancies (62%; 48 of 78) and those with solid tumors (64%; 9 of 14); was 52% (78 of 151) for cases enrolled because of progressive 22 days (range, 1 -510 days; mean, 33 days). The median cumulative dose was 89 mg/kg, with cumulative doses ranging infections (P Å .044).
Duration of therapy. Duration of therapy was analyzed for from 18 mg to 62,100 mg (1 mg/kg to 1,089 mg/kg). ABLC was administered at a median daily dose of 4.91 mg/kg. the entire population. Therapy with ABLC lasted a median of The most common reason for discontinuation of therapy was tion for understanding the safety and efficacy of ABLC in the treatment of patients who are intolerant of or refractory to completion of treatment (187 of 556 cases; 34%) (table 10). The patient's death ended therapy in 175 cases (31%). The conventional antifungal therapy. most common causes of death among these 175 patients were Preclinical studies demonstrated that ABLC was as effective progression of fungal infection in 47% (n Å 83) and progresas (or more effective) and less toxic than conventional amphoterision of underlying diseases in 30% (n Å 53). Treatment was cin B in animal models of candidiasis, aspergillosis, cryptococcoterminated because of adverse events attributable or possibly sis, histoplasmosis, and blastomycosis [12] [13] [14] [15] [16] [17] . These results attributable to ABLC in 49 (9%) of all 556 cases.
formed the experimental foundation for initiation of human clinical trials, which included an open-label study for the treatment of patients with invasive fungal infections who were intolerant of Discussion or refractory to conventional antifungal therapy. The use of ABLC in this setting served an important role in many patients for whom This large clinical trial demonstrated a significant improvethe continuation of amphotericin B therapy would have resulted ment in renal function following the initiation of therapy with in further progressive renal deterioration or in whom standard ABLC, particularly in patients with amphotericin B -induced antifungal chemotherapy appeared to be failing. nephrotoxicity or primary renal dysfunction. Among patients As most patients were receiving amphotericin B, suitable with mycologically confirmed infection, responses were obalternatives for treatment of aggressive invasive mycoses, parserved in those with aspergillosis, zygomycosis, fusariosis, ticularly filamentous fungal infections, were not available. The phaeohyphomycosis, hyalohyphomycosis, disseminated candilack of significant antimicrobial activity of fluconazole against diasis, cryptococcosis, and infections due to dimorphic fungi. many filamentous fungal infections and the lack of reliable oral Response rates varied as a function of the type of infection, bioavailability of itraconazole precluded their use for these the underlying host condition, the pattern of infection, and the critically ill patients requiring parenteral antifungal therapy. reason for enrollment (intolerance vs. progressive infection).
Thus, ABLC was utilized in such settings where there were These findings are from the largest series of cases treated with ABLC described in the current literature and provide a foundafew or no other therapeutic alternatives. The specific types of invasive fungal infections in this study infections, the majority of cases of cryptococcosis occurred in patients with AIDS and those with solid organ transplants, in developed predictably along lines of underlying deficits of host defenses. For example, filamentous fungal infections, espewhom impairment of cell-mediated immunity would be expected to be greatest. cially aspergillosis and fusariosis, tended to predominate in patients with quantitative or qualitative defects in phagocytic Approximately one-half of the patients were enrolled because of renal insufficiency related to amphotericin B or becells, hematologic malignancies, or bone marrow transplants [18 -21] . By comparison, the endemic mycoses, such as histocause of primary renal impairment. Initiation or continuation of the administration of conventional amphotericin B to such plasmosis and coccidioidomycosis, tended to predominate in patients undergoing solid organ transplantation, those with patients would be expected to result in sustained or progressive azotemia during the course of therapy [3] . However, renal solid tumors, and those with AIDS, in which impairment of cell-mediated immunity is the major immunodeficiency.
function in the overall population receiving ABLC continued to significantly improve and then stabilized over the course of Notably, candidiasis tended to be equally distributed among those patients with phagocytic disorders (e.g., neutropenia) and 6 weeks, as illustrated in figure 1 . That the linear regression line with narrow 95% confidence those with impaired cellular immunity. This finding is consisintervals of figure 2 falls below the line of identity also reflects tent with the multifactorial conditions under which candidiasis the improvement of renal function during the course of ABLC in may develop in both neutropenic and nonneutropenic patients the overall study population. The individual points depicted in [22 -24] . In a pattern similar to that of the dimorphic fungal the graph of figure 2 overlap extensively, giving the appearance of fewer points contributing to the curve than the total of 556 actually represented in the data. Moreover, the curve also indicates Table 10 . Reasons for discontinuation of therapy with ABLC.
that while renal function improved in the majority of the population during therapy, points that are above the line of identity
No. (%) of cases indicate that clearly some patients had further renal deterioration.
Reason for discontinuation Total (n Å 556) Evaluable (n Å 291)
Whether this renal deterioration was due to ABLC, administration of concomitant nephrotoxic agents, or other factors such as septic Treatment complete 187 (34) 115 (40) shock cannot be construed from these data.
Patient died 175 (31) 84 (29) Several additional features of this curve bear note. First, the there was a significant decline in serum creatinine levels from / 9c4e$$ju27 05-19-98 12:52:52 cidal UC: CID baseline. Notably, the standard error of the mean for each of C. albicans and human erythrocytes. Another possible mechanism is the relatively reduced concentration of ABLC in the these points is relatively large, suggesting a wide range of individual responses in terms of improvement or deterioration kidney, relative to the high concentration achieved in the reticuloendothelial system [26] . This mechanism alone, however, is of renal function during ABLC treatment.
Nevertheless, improvement or stabilization of renal function not sufficient to explain reduced nephrotoxicity, as ABLC may accumulate in the kidney over time. during ABLC treatment is the antithesis of the effect expected from amphotericin B. Patients with serum creatinine levels A third mechanism, proposed by Janoff et al. [9 -11] , imputes the selective degradation of the lipid complex by fungalstarting at §2.5 mg/dL were more likely to have significant improvement of renal function (figure 4). Fewer points appear derived phospholipases and lipases, which then release amphotericin B directly onto the fungal cells. Such lipases and phosin this curve as a result of multiple overlapping points. In comparison to that in figure 2 , the linear regression line of pholipases are not normally secreted by glomerular cells or renal tubular epithelial cells. A fourth mechanism, proposed figure 4 has slightly wider 95% confidence intervals that encompass the line of identity. These 95% confidence intervals by Lopez-Berestein and colleagues, is the preferential binding of lipid-complexed amphotericin B to high-density lipoproinclude the line of identity at a baseline serum creatinine value of £2.5 mg/dL. However, since all of these patients by definiteins, in comparison with conventional amphotericin B, which is bound to low-density lipoproteins [27] . tion had serum creatinine values §2.5 mg/dL, the relevant portion of the curve remains entirely significant at or below Further corroborating the reduced nephrotoxicity of ABLC, Anaissie et al. investigated the efficacy of ABLC in treatment the line of identity for serum creatinine values §2.5 mg/dL.
As previously mentioned, the curve demonstrates that those of candidemia and disseminated candidiasis in a randomized, multicenter trial comparing ABLC and amphotericin B [28] . individual points appearing above the line of identity reflect patients who have developed progressive renal impairment, One hundred ninety-four patients with candidemia (129 treated with ABLC and 65 with amphotericin B) were enrolled in this while those points below the line of identity represent those patients who had improvement in renal function. Thus, while study in a 2:1 randomization. Patients received either 5.0 mg/(kgrd) of ABLC or 0.6 -1.0 mg/(kgrd) of amphotericin some patients receiving ABLC may develop worsening renal function, the overall trend demonstrates that renal function in B. Baseline characteristics of both groups were similar. The overall success rates were similar (80% for ABLCpatients with baseline renal insufficiency is more likely to improve during ABLC therapy. treated patients and 71% for amphotericin B -treated patients).
The percentage of patients reporting nonrenal adverse events Despite the clear chronological trends in amelioration of elevated baseline serum creatinine levels in the study populain both groups was similar; however, ABLC was significantly less nephrotoxic than amphotericin B. Baseline serum creatition, there was a slight but significant elevation in BUN values (table 4) . While ABLC is the most plausible cause of this nine values doubled for 49% of patients treated with amphotericin B, vs. 28% of those treated with ABLC (P Å .006). trend in elevated BUN levels, there may be little physiological significance of a mean 9% increase in BUN values above an Assessment of the trends of liver function tests showed that there was an increase in total bilirubin values from 4.66 { 0.4 elevated baseline. Other factors, including prerenal azotemia, concomitant treatment with nephrotoxic agents or corticostemg/dL to 6.59 { 0.53 mg/dL (P Å .0001). The contribution, if any, of ABLC to this elevation of serum bilirubin levels roids, and gastrointestinal bleeding, may also contribute to this elevation.
remains uncertain, and its causes are probably multifactorial. The baseline hyperbilirubinemia is a reflection of the critically Nephrotoxicity is the most significant adverse reaction associated with amphotericin B therapy and is usually the factor ill nature of many of these patients enrolled in the study. A concomitant elevation of serum alkaline phosphatase level from that prevents administration of maximally effective therapy. More than 80% of patients treated with amphotericin B develop a mean of 273 { 13 IU/L to 320 { 17 IU/L also coincides with the rise in bilirubin level. Concurrent conditions such as some degree of renal impairment [3] . Patients who receive a cumulative dose of more than 0.5 -1.0 g of amphotericin B sepsis, graft-vs.-host disease, veno-occlusive disease, and endorgan damage from cytotoxic chemotherapy likely contribute are particularly at risk for renal tubular acidosis. Risk factors associated with amphotericin B -induced renal toxicity include to this elevation of bilirubin during the course of therapy. The overall rate of response to ABLC in this study was 57%, total doses of ú4 g, sodium depletion, age of ú30 years, and concomitant therapy with other nephrotoxic drugs.
including complete and partial responses. These findings are consistent with the critically ill condition of these patients at Several mechanisms have been proposed as explanations for the reduced nephrotoxicity of ABLC. The first mechanism enrollment, as they were either intolerant of or refractory to existing antifungal therapy. The response of invasive fungal relates to the observations by Mehta et al. [25] , who described the lipid-mediated selective transfer of ABLC to fungal cell infections to treatment is clearly related to several factors, including underlying disease, reason for enrollment (i.e., intolermembranes and away from mammalian cell membranes, with preferential cytotoxicity for Candida albicans and reduced cyance vs. progressive infection), and pattern of invasive fungal infection. The 91 cases of candidiasis enrolled in this study were associated with an overall favorable response rate of 71% tations, they can provide valuable evidence of the clinical utility of new compounds, particularly when evaluated by expert panand a defined failure rate of 24%. These results are notably quite similar to those of the previously reported randomized els assessing the clinical courses of individual patients.
The responses of aspergillosis, zygomycosis, and fusariosis trial of amphotericin B vs. ABLC [28] . Such response rates are clearly greater in cases of candidiasis than in cases of to ABLC appear to be approximately the same or better than those in previously reported case series with amphotericin B filamentous fungal infection and may reflect a wide range of immunocompromised hosts, encompassing those with solid treatment [18, 20, 21, 29, 30] . Using a case-control analysis, Hiemenz et al. [31] assessed the response rates of patients with organ transplants, HIV infection, and solid tumors, as well as those with hematologic malignancies and bone marrow invasive aspergillosis treated with ABLC in comparison with rates among historical controls treated with amphotericin B.
transplants.
There was a 50% failure rate among patients enrolled with Some of the patients assessed in that review also were analyzed in this study. The observed responses to ABLC were comparacryptococcosis with and without CNS involvement, irrespective of the pattern of infection. The safety and antifungal activble with those to amphotericin B.
Among the mycoses due to filamentous fungi, the rate of ity of ABLC in treatment of CNS cryptococcosis was investigated by Sharkey and colleagues in a cohort of 55 patients response to ABLC was substantially lower in cases of aspergillosis than in cases of zygomycosis and fusariosis. While the randomly assigned to 6 weeks of therapy with ABLC (1.2 -5.0 mg/[kgrd]), with ascending dosages for three sequential lower response rate of aspergillosis might have been predicted from prior studies, the higher positive response rates of zygocohorts, or amphotericin B (0.7 -1.2 mg/[kgrd]) [43] . Among the 21 recipients receiving ABLC in the dosage cohort of 5 mycosis (71%) and fusariosis (82%) are greater than those reported in the literature for similar mycoses. mg/(kgrd) daily for 2 weeks and then thrice weekly for 4 weeks, symptoms and signs resolved for 18 (86%). For example, Boutati and Anaissie reported that fusariosis carries a dismal prognosis and is typically resistant to convenThese data and those reported in this study (64% positive response rate) suggest that ABLC has activity against cryptotional amphotericin B [21] . In the largest reported series of consecutive patients with invasive fusariosis, only 10 (23%) coccal meningitis in patients with and without HIV infection. The comparatively lower efficacy rate in this study vs. that in of 43 patients responded to any type of therapy, and the mortality rate attributable to infection was 67%. That ABLC appears the study by Sharkey et al. may be due to differences in enrollment criteria. Patients in the latter study were enrolled earlier, to have activity against fusariosis may be related to the administration of high dosages and attainment of high tissue concentraat the time of initial diagnosis; in contrast, the study reported herein required that a patient be intolerant of or refractory to tions against this pathogen. These encouraging findings are important in that there are no FDA-approved alternative agents conventional antifungal therapy. Response rates also may vary according to the site of infecto amphotericin B against fusariosis and zygomycosis.
Several individual case reports of fusariosis and zygotion in a given mycosis. For example, in table 6, sinus aspergillosis and single-organ extrapulmonary aspergillosis had a 64% mycosis responding to ABLC also provide further hope that ABLC will be an effective modality against these molds [32 -and 67% response rate, respectively, as compared with pulmonary and disseminated aspergillosis, with response rates of 38% 38]. The potentially beneficial effect of ABLC even on patients who were unresponsive or intolerant of conventional antifungal and 30%, respectively. This difference is likely related in part to the host characteristics, tissue burden of organisms, and therapy suggests an important role for ABLC in managing these difficult patients.
organism-mediated tissue injury in lungs and other vital organs. Surgical curettage or resection in sinusitis and single organ By comparison, among the five cases of phaeohyphomycosis and hyalohyphomycosis the response rate was poor, constitutinfection also may have contributed to an improvement in therapeutic response. Among patients who had a complete or partial ing the highest failure rate amongst all types of infections. Among these infections were two due to P. boydii and one response, surgical debridement was performed in nine (31%) of 29 patients with infection due to filamentous fungi in the each due to B. hawaiiensis, D. gallopava, and Trichoderma species. Dematiaceous molds and P. boydii may be particularly sinus or single-organ extrapulmonary sites.
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The response to ABLC in this report was also a function of therapeutic advance by providing a less nephrotoxic alternative to amphotericin B, particularly when dose-limiting renal imunderlying condition. Table 8 demonstrates a significantly lower response rate among HIV-infected patients than among pairment precludes further administration of amphotericin B. The cost of manufacturing lipid formulations of amphoterithose with other underlying conditions, including hematologic malignancy, bone marrow transplants, solid organ transplants, cin B is currently high. Consequently, the present use of ABLC in an era of cost-containment must be targeted at those patients and solid tumors. Especially notable among patients with AIDS was the poor response to invasive aspergillosis. This finding for whom the therapeutic benefits outweigh fiscal costs. Such patients include those who are clearly intolerant of amphoteriis consistent with those of the Mycoses Study Group, which found that among the different populations, the response of cin B, those with progressive renal insufficiency, those receiving concomitant nephrotoxic agents, those for whom azole theraspergillosis to itraconazole was lowest in HIV-infected patients [44] . Several factors may account for this feature: persisapy is not indicated, and those in whom the risk of renal insufficiency may result in irreversible loss of renal function tence of the underlying immunodeficiency; comorbidity; and combined quantitative and qualitative defects in neutrophils, or marked deterioration of clinical status [49 -51]. Randomized, double-blind multicenter trials should be conmonocytes, and macrophages [45, 46] .
The bone-marrow-transplant population also had a signifisidered the ''gold standard'' for assessing comparative antifungal efficacy. While the study presented here fulfilled an imcantly reduced response, compared with the responses associated with hematologic malignancies and solid organ transportant medical need, its design has several limitations. For example, the participation of multiple centers enrolling individplantation. This lower response rate may be related to the combined factors of neutropenia and profound cell-mediated ual patients precluded prospective collection of radiologic data and permitted variable approaches toward management of these immune impairment, particularly that related to prevention or treatment of graft-vs.-host disease [47, 48] . Indeed, among critically ill patients. The lack of a control group precludes an objective comparison with other antifungal compounds. those patients with persistent graft-vs.-host disease, the need for ongoing immunosuppressive therapy, compounded by the The data presented here are not intended to support the use of ABLC as first-line treatment. Randomized controlled trials immunosuppression induced by graft-vs.-host disease itself, may contribute to a host response that is poorer than in patients will further determine the utility of ABLC vs. conventional amphotericin B for primary treatment of invasive fungal infecwith hematologic malignancies and solid organ transplants.
Antifungal efficacy also was influenced by the reason for tions. Instead, these data provide a critical foundation for understanding the use of ABLC in treatment of patients with proven enrollment. Patients who had intolerance to amphotericin B related to renal insufficiency had a significantly higher response invasive fungal infections who are intolerant of or refractory to conventional antifungal therapy. rate (64%) than did those patients enrolled because of progressive infection (52%). While these differences in responses were predictable, patients in both populations had complete or partial
